Geocann and Nestlé Health Science announced in a press release that they will be launching CBD derived from broad-spectrum hemp extract soft gels in Europe. The soft gels are formulated with patented VESIsorb drug delivery system, which can improve absorption and bioavailability, according to the press release. Geocann has the exclusive global rights to the delivery system.
As the press release explains, the VESIsorb technology has been “well-recognized” as the industry leader for “improving the bioavailability of poorly absorbed natural ingredients, like cannabinoids and terpenes as proven in both well-designed pilot and peer-reviewed published studies.”
The first large-scale production of the product was completed and delivered in early September and included only European resources.
Jesse Lopez, the CEO and founder of Geocann, shared in the press release:
“We are extremely proud to expand our relationship with Nestlé’s healthcare professional brands into Europe after their success in the U.S. market this past year,” said Jesse Lopez, CEO and founder of Geocann. “Their leadership team’s validation of science-backed and clinically-proven hemp products is an important milestone for our industry and provides exceptional credibility to the therapeutic benefits of cannabinoids formulated with VESIsorb®.”
Dr. Barry Ritz, the Chief Science Officer at Pure Encapsulations, also shared in the press release:
“Together with Geocann, we share a passion and commitment to product safety, purity, and performance,” said Dr. Barry Ritz, Chief Science Officer at Pure Encapsulations. “Our partnership is built on a relentless effort to ensure these are the most science-backed CBD products in the world, setting the benchmark for what consumers expect and healthcare professionals demand.”
All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.